Post-cycle and ancillaries compared
Anastrozole vs exemestane
Two aromatase inhibitors, with each figure tied to its own label or trial.
Anastrozole is a selective non-steroidal aromatase inhibitor, and exemestane is an irreversible, steroidal aromatase inactivator.1,2 The Arimidex label gives a mean elimination half-life of 50 hours, and the Aromasin label a mean terminal half-life of about 24 hours.1,2
The labels give one 1 mg tablet of anastrozole once a day, and one 25 mg tablet of exemestane once daily after a meal.1,2
| Fact | Anastrozole (Arimidex) | Exemestane (Aromasin) |
|---|---|---|
| What it is | A selective non-steroidal aromatase inhibitor1 | An irreversible, steroidal aromatase inactivator, structurally related to androstenedione2 |
| How it comes | 1 mg tablets, in bottles of 301 | Tablets of 25 mg2 |
| Half-life | ||
| Studied doses | ||
| Status | US label: breast cancer in postmenopausal women (adjuvant early receptor-positive; first-line advanced receptor-positive or unknown; advanced after tamoxifen)1. WADA lists it among aromatase inhibitors (S4.1), prohibited at all times5 | US label: breast cancer in postmenopausal women after tamoxifen (early disease after 2 to 3 years of it; advanced disease that progressed on it); not premenopausal women2. WADA lists it among aromatase inhibitors (S4.1), prohibited at all times5 |
Last reviewed . Sources are listed below.
How they differ
The Aromasin label states that exemestane acts as a false substrate for the aromatase enzyme and binds irreversibly to it, an effect also known as suicide inhibition.2 The Arimidex label states that food reduces the rate but not the overall extent of anastrozole absorption, and the Aromasin label gives its dose after a meal.1,2
The Aromasin label also states that exemestane has a slight affinity for the androgen receptor and that one metabolite may have androgenic activity.2
Logged in Milligram
- Anastrozole (Arimidex): Too few people logged it to show a share.
- Exemestane (Aromasin): Too few people logged it to show a share.
Shares of people who logged a dose in Milligram in the 90 days to 15 November 2026, shown only where at least 50 people logged three or more doses of the compound.
What is not known
The Arimidex label states that efficacy has not been demonstrated for pubertal boys of adolescent age with gynecomastia, and that its effect in premenopausal women with breast cancer has not been studied.1 The Aromasin label states that the pharmacokinetics of exemestane have not been studied in pediatric patients, while the 2003 study cited above recruited healthy eugonadal subjects aged 14 to 26.2
The 2003 exemestane study in healthy eugonadal subjects states that long-term efficacy and safety will need further study.3
References
- ANI Pharmaceuticals, Inc. ARIMIDEX (anastrozole) tablet, prescribing information (ANI Pharmaceuticals, Inc.). Official label, 2026. DailyMed label
- Pharmacia & Upjohn Company LLC (Pfizer Inc). AROMASIN (exemestane) tablets, for oral use: prescribing information. US prescribing information (DailyMed), 2024. DailyMed label
- Mauras N, Lima J, Patel D, et al. Pharmacokinetics and dose finding of a potent aromatase inhibitor, aromasin (exemestane), in young males. PubMed record, J Clin Endocrinol Metab 2003. PMID 14671195
- van de Velde CJ, Rea D, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. PubMed record, Lancet 2011. PMID 21247627
- World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. Regulator list, 2026. wada-ama.org